


## Lifitegrast sodium

## Chemical Properties

CAS No. :	1119276-80-0
Formula:	C <sub>29</sub> H <sub>23</sub> Cl <sub>2</sub> N <sub>2</sub> NaO <sub>7</sub> S
Molecular Weight:	637.46
Storage:	Store at low temperature Powder: -20°C for 3 years   In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



## Biological Description

Description	Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye.
Targets(IC50)	Integrin

## Solubility Information

Solubility	H <sub>2</sub> O: 80 mg/mL (125.5 mM), Sonication is recommended. DMSO: 80 mg/mL (125.5 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5.18 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5687 mL	7.8436 mL	15.6873 mL
5 mM	0.3137 mL	1.5687 mL	3.1375 mL
10 mM	0.1569 mL	0.7844 mL	1.5687 mL
50 mM	0.0314 mL	0.1569 mL	0.3137 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. *Ocul Surf.* 2016 Apr;14(2):207-15.

Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). *J Ocul Pharmacol Ther.* 2013 May;29(4):395-402.

Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). *Invest Ophthalmol Vis Sci.* 2010 Oct;51(10):5198-204.

Hussar DA, Cheeseman RS 2nd. Lifitegrast, Bezlotoxumab, and Sugammadex sodium. *J Am Pharm Assoc* (2003). 2017 Mar-Apr;57(2):284-287.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481